Dr. Chap provides what women need to know about drug developments for cancer treatment and describes phase one development.
I work with a team of physicians at Saint John’s in whom our interest is developing new drugs for the treatment of ovarian cancer, breast cancer, and a multitude of malignancies. It’s a very exciting area of research in that, these are new drugs that are novel for patients that have failed with the standard or conventional therapies are that are available to them at any place.
By the time that any drug becomes commercially available to a patient, it’s gone through a series of clinical trials to get to that point. So many patients have actually been treated with that drug beforehand. Now when we refer to the earliest phase of these trials, it’s what we refer to as Phase 1 clinical trials. Now these typically are drugs that have maybe been tested in a few humans and are brand new and available where we are really trying to determine what the safety is of these drugs, what the appropriate dosing should be, and then often having, perhaps hints of clinical activity, which means, “How is that patient responding. Is there certain disease that it appears to have some hints of activity, meaning the cancer is actually shrinking.”
So we typically get very excited about that, and then that particular dosing is used to treat a much larger group of patients with that particular dose, which is called the Phase 2 clinical trial.
About Dr. Linnea Chap, M.D.:
Linnea Chap, M.D., is a medical oncologist with an interest in breast cancer treatment. She has been published multiple times and has led several breast and ovarian cancer treatment protocols, including the pioneering use of novel biologic agents such as Herceptin and Avastin. In 2001, Dr. Chap was named, one of “America’s Top Breast Cancer Doctors” by Redbook. Annually, she has also been listed as one of “America’s Top Doctors for Cancer,” published by Michael Connelly. Recognized for her teaching and speaking skills, Dr. Chap has a national reputation where she is frequently called on to speak on the most recent advances in breast cancer treatment.